Curocell Inc. (KOSDAQ:372320)

Market Cap	382.20B -23.8%
Revenue (ttm)	n/a
Net Income	-48.20B
EPS	-3,336.88
Shares Out	15.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,122
Open	26,200
Previous Close	24,700
Day's Range	24,800 - 26,200
52-Week Range	20,650 - 66,000
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Curocell

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 372320

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 20, 2026

Data Sources Report a data error